SCHEMBL7647993

SCHEMBL7647993

CCC(N1Cc2ccccc2C1)S(=O)(=O)c1ccncc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 2/20 0.36
EED O75530 1/20 0.35
DPP8 Q6V1X1 2/20 0.34
DPP9 Q86TI2 2/20 0.34
DPP7 Q9UHL4 2/20 0.34
DPP4 P27487 1/20 0.34
MMP8 P22894 2/20 0.33
MMP3 P08254 1/20 0.33
MAPT P10636 2/20 0.32
KDM4E B2RXH2 1/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
THRB P10828 1/20 0.31
AKR1C3 P42330 1/20 0.31
NPC1 O15118 1/20 0.31
LMNA P02545 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7650642 0.85 NAPRT (0.40) MAPTKDM4EALDH1A1THRBLMNA
SCHEMBL8181127 0.83 KMT2A (0.46) MEN1KMT2AMMP8MMP3MAPT
SCHEMBL7652613 0.78 MEN1 (0.34) NAMPTMEN1KMT2ADPP8DPP9
SCHEMBL8186473 0.77 HTR2C (0.39) MEN1KMT2AALDH1A1RAB9A
SCHEMBL7647370 0.76 TSHR (0.47) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL7966114 0.73 KMT2A (0.53) MEN1KMT2AMMP8MAPTKDM4E
SCHEMBL6097283 0.65 MEN1 (0.46) MEN1KMT2AMAPTKDM4EUSP2
SCHEMBL2632802 0.65 MEN1 (0.50) MEN1KMT2ADPP8DPP9DPP7
SCHEMBL7967069 0.64 ALDH1A1 (0.43) MEN1KMT2AALDH1A1
SCHEMBL13180668 0.63 MEN1 (0.63) MEN1KMT2ADPP8DPP9DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6486173-B2 SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-26 US claimed
US-20010041714-A1 5-HT7 receptor antagonists CAIN GARY A (US) 2001-11-15 US claimed
US-6486173-B2 SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-26 US disclosed
US-20010041714-A1 5-HT7 receptor antagonists CAIN GARY A (US) 2001-11-15 US disclosed
WO-2000000472-A1 5-HT7 RECEPTOR ANTAGONISTS DU PONT PHARMACEUTICALS COMPANY (US) 2000-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041714-A1 5-HT7 receptor antagonists HTR7, HTR5A, HTR1A NAMPT 2255/4885MEN1 1132/4885KMT2A 3243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.